NPC @ HIX Summit: How Rx and Pharma Will Participate in the Exchanges
One of the most pressing issues in the implementation of the Affordable Care Act (ACA) is whether the state health insurance exchanges, or marketplaces, will be effective in achieving their primary aim—ensuring patients have access to health care. Recent studies have suggested that it can be challenging for consumers to figure out which plans offered on the exchanges will cover the specific treatments they need.
One of the most pressing issues in the implementation of the Affordable Care Act (ACA) is whether the state health insurance exchanges, or marketplaces, will be effective in achieving their primary aim—ensuring patients have access to health care. Recent studies have suggested that it can be challenging for consumers to figure out which plans offered on the exchanges will cover the specific treatments they need.
National Pharmaceutical Council Chief Science Officer Robert Dubois, MD, PhD, will take a closer look at the exchanges and access issues during his presentation, “How Pharmaceuticals and Pharmaceutical Companies Will Participate in the Exchanges,” on Thursday, May 15, at 2:15 pm at the Second National Health Insurance Exchange Summit. The Summit will be held at the Capital Hilton in Washington, DC.
Dr. Dubois will cover:
- Why restricted formularies, cost-sharing, coinsurance agreements and higher co-pays limit access to the prescriptions patients need, may increase medication nonadherence and could lead to patient harm;
- Why it is critical that the current quality measures have more breadth and depth to monitor the ACA’s impact; and
- Potential solutions related to easing the financial burden for patients.
To learn more about the role pharmaceuticals play in health insurance exchanges, watch our video interview with Dr. Dubois below.